Hong Kong-listed innovative pharmaceutical concept stocks continue to decline, with Hengrui Pharmaceuticals-B falling more than 7%.

Hong Kong-listed innovative pharmaceutical concept stocks continued to decline, with Gilead Sciences-B falling by more than 7%, Concord Medical, Sino Biopharmaceutical, and Cambiar declining by more than 5%, while Fosun Pharma, Takeda Pharmaceuticals, and Rongchang Biopharmaceutical falling by more than 4%.